| A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (NCT02032277) | AbbVie | 2014-04-02 |
| Cisplatin vs Paclitaxel for Triple Negative Breast Cancer (NCT01982448) | Dana-Farber Cancer Institute | 2014-04-01 |
| Study of the Glutaminase Inhibitor CB-839 in Solid Tumors (NCT02071862) | Calithera Biosciences, Inc | 2014-02-01 |
| LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab (NCT01986426) | Lytix Biopharma AS | 2013-11-01 |
| Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes (NCT02225470) | Eisai Co., Ltd. | 2013-09-26 |
| Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) (NCT01881230) | Celgene | 2013-09-26 |
| GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer (NCT01918306) | Vanderbilt-Ingram Cancer Center | 2013-09-01 |
| RX-5902 Treatment of Subjects With Triple Negative Breast Cancer (NCT02003092) | Rexahn Pharmaceuticals, Inc. | 2013-08-01 |
| NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer (NCT01931163) | Jenny C. Chang, MD | 2013-07-01 |
| Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer (NCT01818063) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-04-25 |
| cMet CAR RNA T Cells Targeting Breast Cancer (NCT01837602) | University of Pennsylvania | 2013-04-01 |
| BRCA and NACT in TNBC Patients (NCT05750719) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2013-01-02 |
| Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer (NCT02012634) | Xijing Hospital | 2013-01-01 |
| Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer (NCT01631552) | Gilead Sciences | 2012-12-17 |
| MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment (NCT01770353) | Ipsen | 2012-11-01 |
| Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (NCT01745367) | AVEO Pharmaceuticals, Inc. | 2012-11-01 |
| Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer (NCT01695057) | University of Southern California | 2012-10-01 |
| Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC (NCT01639248) | CASI pharmaceuticals, Inc. | 2012-07-01 |
| An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer (NCT01677455) | Synta Pharmaceuticals Corp. | 2012-07-01 |
| Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer (NCT01525966) | City of Hope Medical Center | 2012-02-15 |
| An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors (NCT01618136) | Eisai Limited | 2012-01-01 |
| Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment (NCT01520389) | Merrimack Pharmaceuticals | 2012-01-01 |
| A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (NCT01351103) | Novartis Pharmaceuticals | 2011-12-01 |
| A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers (NCT01451632) | Merrimack Pharmaceuticals | 2011-10-01 |
| Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer (NCT01969032) | Russian Academy of Medical Sciences | 2011-08-01 |
| Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients (NCT01372579) | Northwestern University | 2011-08-01 |
| Safety Study of MGA271 in Refractory Cancer (NCT01391143) | MacroGenics | 2011-07-01 |
| Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer (NCT01307891) | University of Alabama at Birmingham | 2011-03-01 |
| Phase II ABT-888 With Cyclophosphamide (NCT01306032) | National Cancer Institute (NCI) | 2011-01-12 |
| Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN) (NCT01216111) | Fudan University | 2011-01-01 |
| Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery (NCT01292083) | University of Southern California | 2011-01-01 |
| Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery (NCT01234532) | University of Maryland, Baltimore | 2010-10-01 |
| Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer (NCT01104259) | University of Washington | 2010-07-01 |
| Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer (NCT01091454) | Alliance for Clinical Trials in Oncology | 2010-06-01 |
| Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer (NCT01151449) | National Cancer Institute (NCI) | 2010-06-01 |
| Triple Negative Breast Cancer Biomarker Study (NCT01111175) | US Oncology Research | 2010-05-01 |
| A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer (NCT03168880) | Tata Memorial Hospital | 2010-04-01 |
| Triple-negative Breast Cancer: a New Perspective on Biomarkers (NCT03539965) | Instituto Nacional de Cancer, Brazil | 2010-01-01 |
| Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors (NCT00998036) | Columbia University | 2009-09-01 |
| MUC1 Vaccine for Triple-negative Breast Cancer (NCT00986609) | Joseph Baar, MD, PhD | 2009-08-19 |
| A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer (NCT00951054) | Nippon Kayaku Co., Ltd. | 2009-02-01 |
| A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer (NCT00813956) | Sanofi | 2008-12-01 |
| Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer (NCT00707707) | AstraZeneca | 2008-09-15 |
| Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer (NCT00733408) | University of Washington | 2008-04-23 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (NCT00031681) | National Cancer Institute (NCI) | 2001-12-01 |
| Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer (NCT02985658) | University of Washington | |